Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PARP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| DNA Damage/Repair | involved_in | process | 0.90 |
| ADP Ribosylation | catalyzes | process | 0.90 |
| DNA Repair | involved_in | process | 0.90 |
| DNA Damage/Repair | catalyzes | process | 0.88 |
| Apoptosis | involved_in | process | 0.80 |
| NAD+ | degrades | chemical | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Nad+ | regulates | compound | 0.95 |
| Parp Inhibitors | traps | drug | 0.90 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| PARP1-NAD+-AIF bioenergetic collapse drives a self-amplifyin | 0.760 | neurodegeneration | What mechanisms drive the self-amplifyin |
| PARP1 Inhibition Therapy | 0.738 | neurodegeneration | TDP-43 phase separation therapeutics for |
| PARP1 Inhibition Blocks Poly(PR)-Triggered DNA Damage and Su | 0.661 | neurodegeneration | What upstream mechanisms trigger p53 act |
| CD38 Inhibition to Preserve NAD+ Pools and Prevent PARP1-Med | 0.380 | metabolomics | Metabolomic signatures of neurodegenerat |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-11 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| DNA Damage Repair Deficiency Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | completed | $7,500,000 |
| Regulated Necrosis Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Transcription-replication conflicts underlie sensitivity to PARP inhibitors. [PMID:38509368] | Petropoulos M, Karamichali A, Rossetti G | Nature | 2024 | 1 |
| PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in o [PMID:38778348] | Liu C, Li J, Xu F, Chen L, Ni M, Wu J, Z | Mol Cancer | 2024 | 1 |
| USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. [PMID:39536107] | Nespolo A, Stefenatti L, Pellarin I, Gam | Sci Adv | 2024 | 1 |
| NAD(+) rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis. [PMID:37683629] | Zhan R, Meng X, Tian D, Xu J, Cui H, Yan | Neuron | 2023 | 1 |
| Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. [PMID:30356214] | Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L | Nature | 2018 | 1 |
| Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1- [PMID:41499130] | Herzog SK, Stevens JH, Gu G, Grimm SL, C | Cancer Res | 2026 | 0 |
| Replicative gaps in DNA damage tolerance, genome instability, and cancer therapy [PMID:41864203] | Falbo L, Costanzo V | Mol Cell | 2026 | 0 |
| Versatile and sensitive detection of mono- and poly(ADP-ribosyl)ation reveals XR [PMID:41922367] | Dauben H, Mihaljević M, Kolvenbach A, Pa | Nat Commun | 2026 | 0 |
| Differential proteomic responses to short-term heat stress in Vechur and crossbr [PMID:41931203] | Anisha J P; Shynu M; Radhika G; Beena V; | Tropical animal health and pro | 2026 | 0 |
| Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 in [PMID:41931484] | Chapman IG, Wu X, Veuger S, Jowsey PA | PLoS One | 2026 | 0 |
| Targeting Poly (ADP-Ribose) Polymerase-1 for the Treatment of Neurodegenerative [PMID:41178110] | Polk S, Rassaeikashuk M, Thilagavathi R, | Chemical biology & drug design | 2025 | 0 |
| Increased nucleotide metabolism alleviates Alzheimer's disease pathology. [PMID:41102145] | ["Yu Y", "Miller M", "Huang A", "Tan B", | Cell death & disease | 2025 | 0 |
| Roles and therapeutic potential of PARP-1 in neurodegenerative diseases. [PMID:41022359] | ["Liu C", "Lai F", "Zhang T", "Mao K", " | Biochemical pharmacology | 2025 | 0 |
| Tipping the PARylation scale: Dysregulation of PAR signaling in Huntington and n [PMID:40905723] | Peng C, Maiuri T, Truant R | Journal of Huntington's diseas | 2025 | 0 |
| Targeting KCNN4 channels modulates microglial activation and apoptosis in a PD-r [PMID:40913912] | ["Hung H", "Li I", "Lin Y", "Yeh T", "Ng | Biomedicine & pharmacotherapy | 2025 | 0 |
| Clinical approaches to overcome PARP inhibitor resistance. [PMID:40442774] | ["Zou Y", "Zhang H", "Chen P", "Tang J", | Molecular cancer | 2025 | 0 |
| PARPs and PARP inhibitors: molecular mechanisms and clinical applications. [PMID:41460301] | Wang F, Guo Z, Carr MJ, Shi W | Molecular biomedicine | 2025 | 0 |
| Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated G [PMID:39480453] | ["Sarkaria J", "Ballman K", "Kizilbash S | JAMA oncology | 2024 | 0 |
| PARP Inhibitors for Breast Cancer Treatment: A Review. [PMID:38512229] | ["Morganti S", "Marra A", "De Angelis C" | JAMA oncology | 2024 | 0 |
| Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migrat [PMID:38396375] | ["Patel J", "Dawson V", "Dawson T"] | Movement disorders : official | 2024 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning PARP in their description or question text
No additional research found